MYL1 and prostate adenocarcinoma: Using our methodology, we identified probable subtype-specific biomarkers, including PARVG and XPO4 in PR+ BRCA, MYL1 in PRAD, KHDRBS1-DLG2 edgetic perturbation in HNSC, and KLF8 in STES.